Savara (NASDAQ:SVRA) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Savara (NASDAQ:SVRA) posted its earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01, reports.

Savara Stock Up 4.0%

Shares of SVRA stock traded up $0.20 during trading hours on Wednesday, hitting $5.12. 2,905,215 shares of the company were exchanged, compared to its average volume of 1,763,256. Savara has a 52 week low of $4.03 and a 52 week high of $7.01. The company has a current ratio of 10.13, a quick ratio of 10.13 and a debt-to-equity ratio of 0.21. The business has a 50 day moving average of $4.97 and a two-hundred day moving average of $5.35. The company has a market capitalization of $1.05 billion, a PE ratio of -8.82 and a beta of 0.32.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Thursday, October 15th. Citigroup reaffirmed a “market outperform” rating on shares of Savara in a research report on Wednesday, October 7th. JPMorgan Chase & Co. initiated coverage on Savara in a report on Wednesday, October 7th. They set an “overweight” rating and a $12.00 price objective on the stock. Royal Bank Of Canada set a $10.00 price objective on Savara in a research report on Wednesday, October 7th. Finally, Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.25.

About Savara

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.